M. Reiter

发表

The use of macroporous gelatin carriers for the cultivation of mammalian cells in fluidised bed reactors

H. Katinger, M. Reiter, O. Hohenwarter, 1990, Cytotechnology.

Avian Suspension Culture Cell Lines for Production of Vaccines and Other Biologicals

M. Reiter, P. N. Barrett, D. Portsmouth, 2014 .

Development of a mammalian cell (Vero) derived candidate influenza virus vaccine.

F. Dorner, M. Reiter, P. N. Barrett, 1998, Vaccine.

Two-dimensional gel electrophoresis for controlling and comparing culture supernatants of mammalian cell culture productions systems

Gerald Blüml, Hermann Katinger, H. Katinger, 2004, Cytotechnology.

Determination of division rates of rCHO cells in high density and immobilized fermentation systems by flow cytometry

H. Katinger, N. Borth, M. Reiter, 2006, Cytotechnology.

A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses

M. Reiter, P. N. Barrett, B. Crowe, 2005, Vaccine.

ON-LINE GLUCOSE CONTROL OF ANIMAL CELL CULTURES IN FLUIDIZED BEDS

H. Katinger, K. Bayer, M. Reiter, 1994 .

OXYGENATION IN FLUIDIZED BED BIOREACTORS USING THE MICROSPARGING TECHNIQUE

H. Katinger, M. Reiter, T. Gaida, 1992 .

DEVELOPMENT OF A NEW TYPE OF MACROPOROUS CARRIER

H. Katinger, M. Reiter, T. Gaida, 1992 .

SCALE-UP OF A FLUIDIZED BED REACTOR OPERATED WITH POROUS GLASS CARRIERS

H. Katinger, M. Reiter, N. Zach, 1992 .

Fluidized Bed Technology: Influence of Fluidization Velocity on Nutrient Consumption and Product Expression

H. Katinger, A. Assadian, M. Reiter, 1998 .

Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.

F. Falkner, M. Reiter, M. Howard, 2007, Vaccine.

Development of a Vero cell-derived influenza whole virus vaccine.

F. Dorner, M. Reiter, P. N. Barrett, 1999, Developments in biological standardization.

A Whole Virus Pandemic Influenza H1N1 Vaccine Is Highly Immunogenic and Protective in Active Immunization and Passive Protection Mouse Models

H. Ehrlich, F. Falkner, M. Reiter, 2010, PloS one.

Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate.

D. Voss, J. Humer, T. Muster, 2009, Vaccine.

Biochemical and functional characterization of recombinant von Willebrand factor produced on a large scale

F. Dorner, M. Reiter, W. Mundt, 1997, Cellular and Molecular Life Sciences CMLS.

Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII.

F. Dorner, M. Reiter, J. Eibl, 1996, Thrombosis research.

A novel mammalian cell (Vero) derived influenza virus vaccine: development, characterization and industrial scale production.

F. Dorner, M. Reiter, P. N. Barrett, 1999, Wiener klinische Wochenschrift.

Expression of recombinant human coagulation factors VII (rFVII) and IX (rFIX) in various cell types, glycosylation analysis, and pharmacokinetic comparison

M. Reiter, M. Graninger, M. Dockal, 2011, BMC proceedings.

Emerging trends in plasma‐free manufacturing of recombinant protein therapeutics expressed in mammalian cells

Thomas R Kreil, M. Reiter, T. Kreil, 2009, Biotechnology journal.

Virus Production Under Suspension Conditions

V. Jäger, O. Merten, M. Reiter, 2014 .

The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans.

F. Dorner, M. Reiter, J. Aaskov, 2007, Vaccine.

Avian cell line - Technology for large scale vaccine production

S. Feigl, M. Reiter, L. Grillberger, 2011, BMC proceedings.

Two-dimensional electrophoresis as a tool for control of quality and consistency in production systems using animal cells

H. Katinger, M. Reiter, T. Gaida, 1992, Cytotechnology.

High-performance liquid chromatographic determination of metabolic products for fermentation control of mammalian cell culture: analysis of carbohydrates, organic acids and orthophosphate using refractive index and ultraviolet detectors.

H. Katinger, A. Jungbauer, M. Reiter, 1989, Journal of chromatography.

Rational Design, Recombinant Preparation, and in Vitro and in Vivo Characterization of Human Prothrombin-derived Hirudin Antagonists*

F. Dorner, M. Reiter, J. Eibl, 1996, The Journal of Biological Chemistry.

Pilot scale production of a human monoclonal antibody against human immunodeficiency virus HIV-1.

H. Katinger, F. Steindl, M. Purtscher, 1989, Journal of biochemical and biophysical methods.

Comparison of protein A, protein G and copolymerized hydroxyapatite for the purification of human monoclonal antibodies.

H. Katinger, F. Steindl, M. Purtscher, 1989, Journal of chromatography.

Structural analysis of recombinant von Willebrand factor produced at industrial scale fermentation of transformed CHO cells co‐expressing recombinant furin

F. Dorner, M. Reiter, H. Schwarz, 1995, FEBS letters.

PROTEIN FREE CULTURE OF R-CHO AND HYBRIDOMA CELLS ON THE MACROPOROUS POLYPORE® CARRIER

H. Katinger, A. Assadian, M. Reiter, 1994 .

Large-scale mammalian cell culture.

M. Reiter, G. Blüml, M Reiter, 1994, Current opinion in biotechnology.

Modular Integrated Fluidized Bed Bioreactor Technology

O. Doblhoff-Dier, F. Unterluggauer, N. Zach, 1991, Bio/Technology.

Flow cytometry and two-dimensional electrophoresis (2-DE) for system evaluation of long term continuous perfused animal cell cultures in macroporous beads

H. Katinger, N. Borth, M. Reiter, 2006, Cytotechnology.

Large-scale mammalian cell culture.

M. Reiter, G. Blüml, 1994, Current opinion in biotechnology.

Characterization of a quail suspension cell line for production of a fusogenic oncolytic virus

U. Reichl, J. Altomonte, Y. Genzel, 2023, Biotechnology and bioengineering.